|View printer-friendly version|
|October 27, 2004 5:21 p.m.|
|Teva Announces Approval Of Medroxyprogesterone Acetate Pre-Filled Syringe|
Jerusalem, Israel, October 27, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL pre-filled syringe. A launch date has not yet been finalized.